Several other equities research analysts also recently weighed in on DBVT. Leerink Swann reissued an “outperform” rating on shares of DBV TECHNOLOGIE/S in a report on Thursday, December 20th. Zacks Investment Research downgraded DBV TECHNOLOGIE/S from a “hold” rating to a “sell” rating in a report on Tuesday, December 11th. JMP Securities reissued a “buy” rating and issued a $20.00 price objective on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. Stifel Nicolaus reissued a “hold” rating and issued a $10.00 price objective on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. Finally, Jefferies Financial Group downgraded DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating and set a $5.25 price objective for the company. in a report on Thursday, December 20th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. DBV TECHNOLOGIE/S currently has an average rating of “Hold” and a consensus price target of $16.03.
DBVT stock opened at $8.76 on Friday. The company has a market capitalization of $466.01 million, a PE ratio of -2.60 and a beta of 1.97. DBV TECHNOLOGIE/S has a twelve month low of $3.60 and a twelve month high of $25.77.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: Why is the LIBOR significant?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.